Yu Kato

8PUBLICATIONS
55CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Te hauora me te oranga ā-whaea, ā-pēpi o te Māori (Māori mothers and babies health and wellbeing)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Feb 22, 2025
Lenvatinib enhances antitumor immunity of anti-PD-1 antibody.

Yu Kato

|Jan 21, 2025
Development of a Microvessel Density Gene Signature and Its Application in Precision Medicine.

Megumi Kuronishi, Yoichi Ozawa, Takayuki Kimura

|Jul 10, 2024
Inhibition of Notch4 Using Novel Neutralizing Antibodies Reduces Tumor Growth in Murine Cancer Models by Targeting the Tumor Endothelium.

Jason W-L Eng, Yu Kato, Yusuke Adachi

|Oct 24, 2022
ER-851, a Novel Selective Inhibitor of AXL, Overcomes Resistance to Antimitotic Drugs.

Shuntaro Tsukamoto, Naoko Hata Sugi, Kyoko Nishibata

|Nov 10, 2021
Inhibition of FGFR Reactivates IFNγ Signaling in Tumor Cells to Enhance the Combined Antitumor Activity of Lenvatinib with Anti-PD-1 Antibodies.

Yusuke Adachi, Hiroshi Kamiyama, Kenji Ichikawa

|Jan 07, 2021
E7386, a Selective Inhibitor of the Interaction between β-Catenin and CBP, Exerts Antitumor Activity in Tumor Models with Activated Canonical Wnt Signaling.

Kazuhiko Yamada, Yusaku Hori, Satoshi Inoue

Pageof 2

Frequent Collaborators

3 joint publications

Yasuhiro Funahashi

2 joint publications

Yoichi Ozawa

2 joint publications

Junji Matsui

2 joint publications

Youya Nakazawa